Article
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.
Nature medicine - 1 Feb 2023
Tian Jun, Chen Jonathan H, Chao Sherry X, Pelka Karin, Giannakis Marios, Hess Julian, Burke Kelly, Jorgji Vjola, Sindurakar Princy, Braverman Jonathan, Mehta Arnav, Oka Tomonori, Huang Mei, Lieb David, Spurrell Maxwell, Allen Jill N, Abrams Thomas A, Clark Jeffrey W, Enzinger Andrea C, Enzinger Peter C, Klempner Samuel J, McCleary Nadine J, Meyerhardt Jeffrey A, Ryan David P, Yurgelun Matthew B, Kanter Katie, Van Seventer Emily E, Baiev Islam, Chi Gary, Jarnagin Joy, Bradford William B, Wong Edmond, Michel Alexa G, Fetter Isobel J, Siravegna Giulia, Gemma Angelo J, Sharpe Arlene, Demehri Shadmehr, Leary Rebecca, Campbell Catarina D, Yilmaz Omer, Getz Gad A, Parikh Aparna R, Hacohen Nir, Corcoran Ryan B
Abstract excerpt
While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack durability. Preclinical data suggest that BRAF/MAPK pathway inhibition may augment the tumor immune response. We performed a proof-of-concept single-arm phase 2 clinical trial of combined PD-1, BRAF and MEK inhibition with sparatlizumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.